📌 Key Takeaways
- On February 24, 2026, Aesthetic Plastic Surgery published
the world’s first randomized controlled trial (RCT) of Profhilo®.
Both the Profhilo and placebo groups showed increased dermal thickness,
but Profhilo did not demonstrate a statistically significant advantage over placebo. - 54.5% of participants reported dissatisfaction with their results.
However, improvements in wrinkles and pore size were observed. - Critical limitation: only 12 participants over an 8-week follow-up.
This does not constitute proof of inefficacy. - The fact that the world’s first RCT was conducted at all
marks a turning point for evidence-based aesthetic medicine.
“I was recommended Profhilo at a clinic — they called it a bio-remodeler
that rejuvenates skin from within. But does it actually work?”
This question is more common than ever in aesthetic medicine consultations.
On February 24, 2026, the world’s first RCT of Profhilo® was published —
and the findings were, in some ways, unexpected.
But reading them as simply “it doesn’t work” would be a mistake.
INDEX
- Study Snapshot: Key Numbers at a Glance
- What Changed — and What Didn’t: Reading the Results Accurately
- Why Profhilo Didn’t Beat Placebo: Three Critical Contexts
- Understanding Evidence Levels Changes How You Choose Treatments
- Three Questions to Ask Your Clinician Before Any Aesthetic Treatment
- Summary
- Frequently Asked Questions
Study Snapshot: Key Numbers at a Glance
Trial Design
RCT
Split-face method
World’s first
RCT
Split-face method
World’s first
Participants
12
Female subjects
Small sample size
12
Female subjects
Small sample size
Follow-up Period
8
Weeks
Short-term assessment
8
Weeks
Short-term assessment
Patient Dissatisfaction
54.5%
Reported dissatisfaction
45.5% satisfied or neutral
54.5%
Reported dissatisfaction
45.5% satisfied or neutral
What Changed — and What Didn’t: Reading the Results Accurately
📏
Primary Endpoint
Dermal thickness increased
(no advantage over placebo)
Primary Endpoint
Dermal thickness increased
(no advantage over placebo)
🌀
Secondary Endpoints
Wrinkles & pore size
showed improvement
Secondary Endpoints
Wrinkles & pore size
showed improvement
😔
Patient Satisfaction
54.5%
dissatisfied
Patient Satisfaction
54.5%
dissatisfied
🧠
Psychological Score
Perceived aging
improved
Psychological Score
Perceived aging
improved
Source: Aesthetic Plastic Surgery, February 24, 2026 · DOI: 10.1007/s00266-026-05634-4
Why Profhilo Didn’t Beat Placebo: Three Critical Contexts
①
The problem with “dermal thickness” as a metric
Profhilo® is marketed for improvements in hydration, elasticity, and firmness —
not for increasing dermal thickness.
The trial measured what was measurable, not necessarily what Profhilo claims to do.
not for increasing dermal thickness.
The trial measured what was measurable, not necessarily what Profhilo claims to do.
↓
②
The sample size problem (n=12)
Twelve participants is extremely small for detecting statistical significance.
The authors themselves acknowledged sample size as a key limitation of the study.
The authors themselves acknowledged sample size as a key limitation of the study.
↓
③
Wrinkles and pore size did show measurable change
While dermal thickness increased in both groups without significant difference,
Profhilo did show improvements in wrinkles and pore reduction.
This is a textbook case of how the choice of measurement endpoint
shapes what a study can and cannot see.
Profhilo did show improvements in wrinkles and pore reduction.
This is a textbook case of how the choice of measurement endpoint
shapes what a study can and cannot see.
Understanding Evidence Levels Changes How You Choose Treatments
Medical Evidence Hierarchy (highest to lowest)
Lv.1
RCT & Meta-analysis ← Profhilo reached this level for the first time in 2026
RCT & Meta-analysis ← Profhilo reached this level for the first time in 2026
Lv.2
Cohort studies & case-control studies
Cohort studies & case-control studies
Lv.3
Case reports & case series ← where most aesthetic treatments remain
Case reports & case series ← where most aesthetic treatments remain
Lv.4
Expert opinion, animal studies, clinical experience
Expert opinion, animal studies, clinical experience
⚠️ Key takeaway: A single negative RCT does not prove a treatment is ineffective.
It means: “In one RCT of 12 participants over 8 weeks,
no statistically significant difference over placebo was demonstrated.” That’s a narrow, specific finding.
It means: “In one RCT of 12 participants over 8 weeks,
no statistically significant difference over placebo was demonstrated.” That’s a narrow, specific finding.
💡 What Is an RCT (Randomized Controlled Trial)?
An RCT is the gold standard of clinical evidence.
Participants are randomly assigned to a treatment group or a placebo group,
eliminating the “belief effect” to measure true efficacy.
RCTs are rare in aesthetic medicine —
making this Profhilo® trial a genuinely significant milestone.
Three Questions to Ask Your Clinician Before Any Aesthetic Treatment
📋 Ask these before agreeing to any procedure
Q1“Is there a randomized controlled trial (RCT) supporting this treatment?”
Q2“Which published studies or conference presentations is this based on?”
Q3“Has this been approved or cleared by the FDA, CE, or an equivalent regulatory body?”
A clinician’s ability to answer these clearly is itself a meaningful signal of their practice quality.
Kenichi Adachi, Editor-in-Chief
“Profhilo showed no significant advantage over placebo in this RCT”
does not mean “Profhilo doesn’t work.”
But it also means we cannot yet say “the evidence is sufficient.”
What matters most is that the world’s first RCT was conducted at all.
Accurate answers will emerge as more trials accumulate.
“What level of evidence supports this treatment?” —
Patients who can ask this question raise the standard of aesthetic medicine for everyone.
Kenichi Adachi, Editor-in-Chief
Summary
- The world’s first RCT of Profhilo® was published in Aesthetic Plastic Surgery
on February 24, 2026.
Both the Profhilo and placebo groups showed increased dermal thickness,
but Profhilo did not significantly outperform placebo.
54.5% of participants reported dissatisfaction with outcomes. - Improvements in wrinkles and pore size were reported,
so the treatment cannot be dismissed as entirely ineffective.
The authors themselves acknowledged the small sample size as a key limitation. - The significance lies in the fact that a rigorous RCT was conducted at all.
More trials will be needed before definitive conclusions can be drawn. - Asking “what evidence supports this treatment?” before any procedure
is one of the most effective forms of consumer self-protection in aesthetic medicine.
Frequently Asked Questions
Should I still consider getting Profhilo® treatments?
NERO does not make a blanket recommendation either way.
This study found that Profhilo did not significantly outperform placebo
on the primary endpoint of dermal thickness.
Clarify what you personally expect from the treatment,
then ask your clinician: “How do you interpret the results of this RCT?”
Their answer will tell you a great deal about their approach to evidence.
This study found that Profhilo did not significantly outperform placebo
on the primary endpoint of dermal thickness.
Clarify what you personally expect from the treatment,
then ask your clinician: “How do you interpret the results of this RCT?”
Their answer will tell you a great deal about their approach to evidence.
What other bio-remodelers exist beyond Profhilo®?
Notable alternatives include Juvelook, Lenisna, and Gouri,
each with different active ingredients, mechanisms of action,
and levels of clinical evidence.
Always ask your clinician what evidence exists for any specific product
before proceeding with treatment.
each with different active ingredients, mechanisms of action,
and levels of clinical evidence.
Always ask your clinician what evidence exists for any specific product
before proceeding with treatment.
Can a treatment still be worth considering even after a negative RCT?
Yes. A single negative RCT does not prove a treatment is ineffective —
it means the evidence is currently insufficient to confirm superiority over placebo.
Given the small sample and short follow-up in this trial,
the key question is how your clinician interprets the data
and how you weigh that information in your own decision-making.
it means the evidence is currently insufficient to confirm superiority over placebo.
Given the small sample and short follow-up in this trial,
the key question is how your clinician interprets the data
and how you weigh that information in your own decision-making.
Sources
Aesthet Plast Surg. 2026 Feb 24. “Evaluating the Efficacy of Polynucleotide and Hyaluronic Acid Hybrid Polymer (Profhilo®) on Perioral Skin: A Double-Blind, Randomized Controlled Trial.” DOI: 10.1007/s00266-026-05634-4. Springer Nature.
